- Home
- CLLS
CLLS
Cellectis S.A.
as 11-15-2024 4:00pm EST
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 240.2M | IPO Year: | 2007 |
| Target Price: | $7.00 | AVG Volume (30 days): | 93.0K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.70 - $3.77 | Next Earning Date: | 11-04-2024 |
| Revenue: | $36,042,000 | Revenue Growth: | 46.96% |
| Revenue Growth (this year): | 271.02% | Revenue Growth (next year): | 33.48% |
Latest Cellectis S.A. News
CLLS Breaking Stock News: Dive into CLLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Monthly information on share capital and company voting rights
GlobeNewswire
12 days ago
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
GlobeNewswire
13 days ago
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
GuruFocus.com
13 days ago
What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings
GlobeNewswire
18 days ago
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
TipRanks
25 days ago
Cellectis Presents New Gene-Editing Breakthroughs
GlobeNewswire
a month ago
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
GlobeNewswire
2 months ago
Monthly information on share capital and company voting rights
Compare CLLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLLS Cellectis S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.